News

This chart caught our eye: the largest deals of the past decade in Diagnostics, Precision Medicine, and Life Science Tools show just how quickly innovation (and consolidation) is accelerating across the sector. 🔹 Life science tools and diagnostics remain hotbeds for strategic investment, with multiple $10B+ deals over the past few years as companies race to expand capabilities in NGS, liquid biopsy, antibody-based diagnostics, molecular testing, and more. 🔹 Even the smaller" deals (in the $2B–$8B range) highlight critical areas of growth: immunoassays, proteomics, sequencing technologies, and platform tools enabling next-generation research. What's clear: Innovation in diagnostics and precision medicine isn't slowing down — it's accelerating through strategic acquisitions that reshape the competitive landscape."